FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112464517> ?p ?o ?g. }

• W2112464517 abstract "Abstract 3908 INTRODUCTION Chemoimmunotherapy, namely the combination of fludarabine, cyclophosphamide and rituximab (FCR), results in a higher response rate and a longer progression-free survival in patients with chronic lymphocytic leukemia (CLL). There is also evidence coming from several historical comparisons, observational, and epidemiological studies and, above all, a large randomized clinical trial (German CLL Study Group – Hallek M et al , Lancet 2010) that FCR prolongs survival. Since additional randomized studies to validate the superiority of FCR over older therapies in CLL are difficult to envisage, other approaches to confirm this observation are worth to be considered. AIM The aim of this study was to ascertain whether chemoimmunotherapy given at any time over the course of the disease, independently of the treatment phase, prolonged survival in a group of unselected patients with CLL from the Hospital Clinic of Barcelona. MATERIALS AND METHODS Out of 1042 consecutive patients diagnosed and followed-up from 1980 to December 2010, we selected 484 patients who received at some point of their disease evolution: (1) alkylating agents and no purine analogs (PA) nor rituximab (R) ( no PA no R ) (n=211; of which 67 PA ) (n=159). (3) PA plus rituximab ( PA+R ) (n=114). Clinical information (age, sex, Binet stage) and laboratory characteristics (β2-microglobulin, CD38, ZAP-70, genomic alterations, IGHV mutational status) at disease presentation, treatment, and follow-up was obtained from a database prospectively managed at our institution from the 1970s onwards. All treated patients were included in the analysis regardless of the number of cycles of therapy given and independently of whether they had participated in clinical trials or not. RESULTS The median age (range) of the whole series (n=340, 222M/118F) was 56 (24–84) years. The three groups were well balanced for key clinical characteristics such as age, sex, and Binet stage at treatment. It should be noted that patients older than 65 years were initially excluded from the analysis to avoid a bias in the results due to the general worse prognosis of older patients. On the other hand, patients from the PA and PA+R groups presented poorer risk prognosis factors such as a higher expression of CD38 (p=0.006), ZAP-70 (p=0.052), and adverse cytogenetic abnormalities (p=0.026) or unmutated IGHV genes (p=0.005) than those in the no PA no R group. After a median follow up of 9.4 years (range, 0.3–21), 148 (44%) patients remain alive. At 10 years, the overall survival of the PA+R group was 65% (95% CI, 53–77%) compared with 43% (35–51%) and 43% (31–54%) for the no PA no R and PA groups, respectively (p When all patients who did not receive PA or R were included in the study (n=211), the statistically significant difference was, not surprisingly, maintained (data not shown). In addition, patients from both the PA group and the PA+R group had poorer prognostic features. These data are in keeping with a conservative therapeutic approach in patients with low-risk disease and a poorer risk of patients treated with PA with or without R. This is also an additional argument in favor of the effectiveness of chemoimmunotherapy in high-risk patients. Interestingly, when survival of patients treated with PA+R was analyzed according to the time at which treatment was administered (first line, n=55 vs. ≥ second line, n=59), no differences were observed (p= 0.8) (Figure 2) CONCLUSION Chemoimmunotherapy prolongs survival of patients with CLL. Moreover, this effect could be independent of the phase of the disease at which chemoimmunotherapy is given. Disclosures: No relevant conflicts of interest to declare." @default.
• W2112464517 created "2016-06-24" @default.
• W2112464517 creator A5000087123 @default.
• W2112464517 creator A5006963159 @default.
• W2112464517 creator A5007551486 @default.
• W2112464517 creator A5024516606 @default.
• W2112464517 creator A5025723075 @default.
• W2112464517 creator A5027929010 @default.
• W2112464517 creator A5033486428 @default.
• W2112464517 creator A5061167008 @default.
• W2112464517 creator A5063421244 @default.
• W2112464517 creator A5068240503 @default.
• W2112464517 creator A5088963827 @default.
• W2112464517 date "2011-10-01" @default.
• W2112464517 modified "2023-10-06" @default.
• W2112464517 title "5.17 Chemoimmunotherapy Improves Survival of Patients with Chronic Lymphocytic Leukemia" @default.
• W2112464517 cites W1974855794 @default.
• W2112464517 cites W2001850157 @default.
• W2112464517 cites W2063204645 @default.
• W2112464517 cites W2108726442 @default.
• W2112464517 cites W2140606816 @default.
• W2112464517 doi "https://doi.org/10.1016/j.clml.2011.09.171" @default.
• W2112464517 hasPublicationYear "2011" @default.
• W2112464517 type Work @default.
• W2112464517 sameAs 2112464517 @default.
• W2112464517 citedByCount "0" @default.
• W2112464517 crossrefType "journal-article" @default.
• W2112464517 hasAuthorship W2112464517A5000087123 @default.
• W2112464517 hasAuthorship W2112464517A5006963159 @default.
• W2112464517 hasAuthorship W2112464517A5007551486 @default.
• W2112464517 hasAuthorship W2112464517A5024516606 @default.
• W2112464517 hasAuthorship W2112464517A5025723075 @default.
• W2112464517 hasAuthorship W2112464517A5027929010 @default.
• W2112464517 hasAuthorship W2112464517A5033486428 @default.
• W2112464517 hasAuthorship W2112464517A5061167008 @default.
• W2112464517 hasAuthorship W2112464517A5063421244 @default.
• W2112464517 hasAuthorship W2112464517A5068240503 @default.
• W2112464517 hasAuthorship W2112464517A5088963827 @default.
• W2112464517 hasConcept C126322002 @default.
• W2112464517 hasConcept C141071460 @default.
• W2112464517 hasConcept C143998085 @default.
• W2112464517 hasConcept C168563851 @default.
• W2112464517 hasConcept C2776694085 @default.
• W2112464517 hasConcept C2776755627 @default.
• W2112464517 hasConcept C2777609679 @default.
• W2112464517 hasConcept C2777866208 @default.
• W2112464517 hasConcept C2777938653 @default.
• W2112464517 hasConcept C2778461978 @default.
• W2112464517 hasConcept C2779015954 @default.
• W2112464517 hasConcept C2779263901 @default.
• W2112464517 hasConcept C2779338263 @default.
• W2112464517 hasConcept C2780653079 @default.
• W2112464517 hasConcept C2780790343 @default.
• W2112464517 hasConcept C2911091166 @default.
• W2112464517 hasConcept C71924100 @default.
• W2112464517 hasConceptScore W2112464517C126322002 @default.
• W2112464517 hasConceptScore W2112464517C141071460 @default.
• W2112464517 hasConceptScore W2112464517C143998085 @default.
• W2112464517 hasConceptScore W2112464517C168563851 @default.
• W2112464517 hasConceptScore W2112464517C2776694085 @default.
• W2112464517 hasConceptScore W2112464517C2776755627 @default.
• W2112464517 hasConceptScore W2112464517C2777609679 @default.
• W2112464517 hasConceptScore W2112464517C2777866208 @default.
• W2112464517 hasConceptScore W2112464517C2777938653 @default.
• W2112464517 hasConceptScore W2112464517C2778461978 @default.
• W2112464517 hasConceptScore W2112464517C2779015954 @default.
• W2112464517 hasConceptScore W2112464517C2779263901 @default.
• W2112464517 hasConceptScore W2112464517C2779338263 @default.
• W2112464517 hasConceptScore W2112464517C2780653079 @default.
• W2112464517 hasConceptScore W2112464517C2780790343 @default.
• W2112464517 hasConceptScore W2112464517C2911091166 @default.
• W2112464517 hasConceptScore W2112464517C71924100 @default.
• W2112464517 hasLocation W21124645171 @default.
• W2112464517 hasOpenAccess W2112464517 @default.
• W2112464517 hasPrimaryLocation W21124645171 @default.
• W2112464517 hasRelatedWork W126125533 @default.
• W2112464517 hasRelatedWork W182289156 @default.
• W2112464517 hasRelatedWork W2000818610 @default.
• W2112464517 hasRelatedWork W2078045353 @default.
• W2112464517 hasRelatedWork W2085074066 @default.
• W2112464517 hasRelatedWork W2485364093 @default.
• W2112464517 hasRelatedWork W2503439872 @default.
• W2112464517 hasRelatedWork W2555334284 @default.
• W2112464517 hasRelatedWork W2560102062 @default.
• W2112464517 hasRelatedWork W2571883057 @default.
• W2112464517 hasRelatedWork W2581301991 @default.
• W2112464517 hasRelatedWork W2588070030 @default.
• W2112464517 hasRelatedWork W2590392808 @default.
• W2112464517 hasRelatedWork W2593055279 @default.
• W2112464517 hasRelatedWork W2901646610 @default.
• W2112464517 hasRelatedWork W2979337275 @default.
• W2112464517 hasRelatedWork W3095595977 @default.
• W2112464517 hasRelatedWork W3196771116 @default.
• W2112464517 hasRelatedWork W616428357 @default.
• W2112464517 hasRelatedWork W1745646308 @default.
• W2112464517 isParatext "false" @default.
• W2112464517 isRetracted "false" @default.
• W2112464517 magId "2112464517" @default.
• W2112464517 workType "article" @default.